Liquidia Corporation (LQDA)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Liquidia Technologies, Inc.(LQDA) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / September 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Liquidia Corporation Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LQDA
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
An Investigation Has Commenced on Behalf of Liquidia Corporation Shareholders. Contact Levi & Korsinsky to Discuss your LQDA Losses.
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm Has Opened An Inquiry Into Whether Liquidia Corporation Committed Securities Fraud And Impacted Investors Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATTENTION Liquidia Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Liquidia Technologies, Inc.(LQDA) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Shareholders that lost money on Liquidia Corporation(LQDA) should contact Levi & Korsinsky about Securities Fraud Investigation - LQDA
NEW YORK, NY / ACCESSWIRE / August 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Corporation Is Under Investigation For Potential Securities Law Violations, And The Schall Law Firm Is Urging Shareholders To Participate
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Liquidia Corporation (LQDA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Liquidia Corp. May Be Liable To Compensate Shareholders And The Schall Law Firm Wants The Public's Help In An Investigation
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
